Arrowhead Pharmaceuticals Prices Upsized Offerings of Convertible Senior Notes, Common Stock and Pre-Funded Warrants
Arrowhead Pharmaceuticals Announces NMPA Approval of REDEMPLO® for Familial Chylomicronemia Syndrome in China
Arrowhead Pharmaceuticals Announces Interim Clinical Data on RNAi-based Obesity Candidates Showing Weight Loss in Obese Patients with Diabetes and Improved Measures of Body Composition
Arrowhead Pharmaceuticals Announces Health Canada Approval of REDEMPLO to Reduce Triglycerides in Adults with Familial Chylomicronemia Syndrome
Arrowhead Pharmaceuticals Initiates Phase 1/2a Study of ARO-MAPT for the Treatment of Alzheimer's Disease and Other Tauopathies
Arrowhead Pharmaceuticals Receives FDA Breakthrough Therapy Designation for Plozasiran in Severe Hypertriglyceridemia
Arrowhead Pharmaceuticals Announces FDA Approval of REDEMPLO® to Reduce Triglycerides in Adults with Familial Chylomicronemia Syndrome
